No Data
No Data
Vicom Ltd. (301126.SZ): Jiachen Hospital has established an Assisted Reproduction (IVF) Center, setting up embryo culture room, semen processing room, transplantation surgery room and embryo freezing room.
On August 14th, Gelunhui reported that Vicom Ltd. (301126.SZ) stated on the investor interactive platform that Jia Chen Hospital, which is owned by the company, is applying for a review of a third-level specialized hospital. Due to the high barriers of assisted reproductive technology, the license application process is lengthy, and the approval criteria are strict, there is uncertainty about the prospects for the company to continue to carry out assisted reproduction business. Jia Chen Hospital has established an assisted reproduction (IVF) center and established embryo culture rooms, sperm processing rooms, transplantation operating rooms, and embryo freezing rooms. Currently, the hospital is making further preparations and construction in accordance with the requirements of "human assisted reproductive technology specifications." After obtaining the qualification of human assisted reproductive licensing, the hospital will begin its operations.
Vicom Ltd (301126.SZ) has repurchased 0.43% of its shares.
On August 1st, Glon Hui announced that until July 31, 2024, Vicom Ltd (301126.SZ) had repurchased 892,300 shares of the company through a share repurchase special securities account by means of centralized bidding trading, accounting for 0.43% of the company's current total share capital. The highest fill price was 9.76 yuan/share, the lowest fill price was 8.77 yuan/share, and the total amount of funds used was 8,118,966.00 yuan (excluding transaction commission and other fees). This buyback meets the requirements of the company's buyback plan and relevant laws and regulations.
Hunan Dajiaweikang Pharmaceutical Industry: 2024 Interim Performance Forecast
As of July 10th, 2024, Vicom Ltd (301126.SZ) had 15,793 shareholders.
On July 11th, Gelonhui reported that as of July 10th, 2024, the number of shareholders of Vicom Ltd. (301126.SZ) was 15,793 on the investor interactive platform.
Vicom Ltd (301126.SZ): The business of the pharmaceutical industry mainly focuses on the layout of Chinese patent medicine products, conducting the production and processing of pharmaceuticals, medical devices, food, and pharmaceutical research and develo
On June 19th, Gelonhui reported that Vicom Ltd. (301126.SZ) stated on the investor interaction platform that the company owns two pharmaceutical companies, Dajia Biopharmaceutical and Tianji Caotang, to build the company's pharmaceutical industry system. Currently, the company's pharmaceutical industry business mainly focuses on the layout of Chinese patent medicine products, conducts production and processing of pharmaceuticals, medical devices, food and other drugs research and development. The company's research product, Oseltamivir phosphate oral syrup, has completed CDE filing, and the clinical BE trial of atorvastatin calcium tablets is ongoing.
Vicom Ltd. (301126.SZ) specific shareholder, Qi Investment, and its concerted actors have jointly reduced their shareholding by 100,000 shares.
Vicom Ltd (301126.SZ) announced that specific shareholder Ningbo Meishan Free Trade Port Area Liangji Private Equity Investment Partnership Enterprise (Limited Partnership) ('Liangji Investment') and its concerted person Ningbo Meishan Free Trade Port Area Chunkang Equity Investment Partnership Enterprise (Limited Partnership) ('Chunkang Investment', together with 'Liangji Investment' referred to as 'this unit') have fulfilled their shareholding reduction plan. The above shareholders have reduced a total of 100,000 shares, with a reduction ratio of 0.04853%.
No Data